C.R. Bard, Inc. (BCR) Holdings Maintained by Peapack Gladstone Financial Corp
Peapack Gladstone Financial Corp held its stake in shares of C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,100 shares of the medical instruments supplier’s stock at the close of the second quarter. Peapack Gladstone Financial Corp’s holdings in C.R. Bard were worth $980,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC grew its holdings in shares of C.R. Bard by 24.2% during the second quarter. Janus Henderson Group PLC now owns 285,446 shares of the medical instruments supplier’s stock worth $90,235,000 after purchasing an additional 55,588 shares in the last quarter. Halcyon Management Partners LP purchased a new position in shares of C.R. Bard during the second quarter worth about $25,746,000. GLG Partners LP purchased a new position in shares of C.R. Bard during the second quarter worth about $17,861,000. Glovista Investments LLC purchased a new position in shares of C.R. Bard during the second quarter worth about $221,000. Finally, Tudor Investment Corp ET AL grew its holdings in shares of C.R. Bard by 8,096.0% during the second quarter. Tudor Investment Corp ET AL now owns 151,871 shares of the medical instruments supplier’s stock worth $48,008,000 after purchasing an additional 150,018 shares in the last quarter. 79.22% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “C.R. Bard, Inc. (BCR) Holdings Maintained by Peapack Gladstone Financial Corp” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/06/c-r-bard-inc-bcr-holdings-maintained-by-peapack-gladstone-financial-corp.html.
In other news, insider Sharon M. Luboff sold 30,252 shares of C.R. Bard stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $320.00, for a total value of $9,680,640.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the transaction, the insider now owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The disclosure for this sale can be found here. Company insiders own 0.80% of the company’s stock.
Shares of C.R. Bard, Inc. (BCR) traded up 0.15% during mid-day trading on Friday, reaching $321.45. The company’s stock had a trading volume of 48,753 shares. The stock has a market capitalization of $23.36 billion, a P/E ratio of 42.20 and a beta of 0.58. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $324.58. The company’s 50-day moving average price is $319.92 and its 200-day moving average price is $304.54.
C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.54 EPS. On average, equities research analysts forecast that C.R. Bard, Inc. will post $11.81 earnings per share for the current fiscal year.
BCR has been the subject of several recent analyst reports. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $360.00 price objective for the company in a report on Monday, July 31st. Jefferies Group LLC reissued a “hold” rating on shares of C.R. Bard in a report on Thursday, August 3rd. BidaskClub lowered C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, BMO Capital Markets reissued a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $292.00.
C.R. Bard Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.